Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.

Prabhu VV, Talekar MK, Lulla AR, Kline CLB, Zhou L, Hall J, Van den Heuvel APJ, Dicker DT, Babar J, Grupp SA, Garnett MJ, McDermott U, Benes CH, Pu JJ, Claxton DF, Khan N, Oster W, Allen JE, El-Deiry WS.

Cell Cycle. 2018;17(4):468-478. doi: 10.1080/15384101.2017.1403689. Epub 2018 Feb 19.

PMID:
29157092
2.

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.

Lev A, Lulla AR, Wagner J, Ralff MD, Kiehl JB, Zhou Y, Benes CH, Prabhu VV, Oster W, Astsaturov I, Dicker DT, El-Deiry WS.

Oncotarget. 2017 Sep 12;8(47):81776-81793. doi: 10.18632/oncotarget.20819. eCollection 2017 Oct 10.

3.

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma.

Arrillaga-Romany I, Chi AS, Allen JE, Oster W, Wen PY, Batchelor TT.

Oncotarget. 2017 May 12;8(45):79298-79304. doi: 10.18632/oncotarget.17837. eCollection 2017 Oct 3.

4.

ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways.

Ni X, Zhang X, Hu CH, Langridge T, Tarapore RS, Allen JE, Oster W, Duvic M.

Oncotarget. 2017 Jun 27;8(37):61761-61776. doi: 10.18632/oncotarget.18688. eCollection 2017 Sep 22.

5.

Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.

Wagner J, Kline CL, Ralff MD, Lev A, Lulla A, Zhou L, Olson GL, Nallaganchu BR, Benes CH, Allen JE, Prabhu VV, Stogniew M, Oster W, El-Deiry WS.

Cell Cycle. 2017 Oct 2;16(19):1790-1799. doi: 10.1080/15384101.2017.1325046. Epub 2017 May 10.

PMID:
28489985
6.

ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.

Ralff MD, Kline CLB, Küçükkase OC, Wagner J, Lim B, Dicker DT, Prabhu VV, Oster W, El-Deiry WS.

Mol Cancer Ther. 2017 Jul;16(7):1290-1298. doi: 10.1158/1535-7163.MCT-17-0121. Epub 2017 Apr 19.

7.

First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors.

Stein MN, Bertino JR, Kaufman HL, Mayer T, Moss R, Silk A, Chan N, Malhotra J, Rodriguez L, Aisner J, Aiken RD, Haffty BG, DiPaola RS, Saunders T, Zloza A, Damare S, Beckett Y, Yu B, Najmi S, Gabel C, Dickerson S, Zheng L, El-Deiry WS, Allen JE, Stogniew M, Oster W, Mehnert JM.

Clin Cancer Res. 2017 Aug 1;23(15):4163-4169. doi: 10.1158/1078-0432.CCR-16-2658. Epub 2017 Mar 22.

PMID:
28331050
8.

Discovery and clinical introduction of first-in-class imipridone ONC201.

Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS.

Oncotarget. 2016 Nov 8;7(45):74380-74392. doi: 10.18632/oncotarget.11814. Review.

9.

NFκB induces overexpression of bovine FcRn: a novel mechanism that further contributes to the enhanced immune response in genetically modified animals carrying extra copies of FcRn.

Cervenak J, Doleschall M, Bender B, Mayer B, Schneider Z, Doleschall Z, Zhao Y, Bősze Z, Hammarström L, Oster W, Kacskovics I.

MAbs. 2013 Nov-Dec;5(6):860-71. doi: 10.4161/mabs.26507.

10.

Chemoprotective and radioprotective effects of amifostine: an update of clinical trials.

Capizzi RL, Oster W.

Int J Hematol. 2000 Dec;72(4):425-35. Review.

PMID:
11197208
11.

Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer.

Wasserman T, Mackowiak JI, Brizel DM, Oster W, Zhang J, Peeples PJ, Sauer R.

Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1035-9.

PMID:
11072160
12.

Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.

Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W, Sauer R.

J Clin Oncol. 2000 Oct 1;18(19):3339-45. Erratum in: J Clin Oncol 2000 Dec 15;18(24):4110-1.

PMID:
11013273
13.

Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group.

Planting AS, Catimel G, de Mulder PH, de Graeff A, Höppener F, Verweij J, Oster W, Vermorken JB.

Ann Oncol. 1999 Jun;10(6):693-700.

PMID:
10442192
15.

Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.

Rustin GJ, Nelstrop AE, Crawford M, Ledermann J, Lambert HE, Coleman R, Johnson J, Evans H, Brown S, Oster W.

J Clin Oncol. 1997 Jan;15(1):172-6.

PMID:
8996139
16.
17.
18.

Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.

Betticher DC, Anderson H, Ranson M, Meely K, Oster W, Thatcher N.

Br J Cancer. 1995 Dec;72(6):1551-5.

19.
20.

A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.

Jodrell DI, Oster W, Kerr DJ, Canney PA, Yosef H, Steward WP, Kaye SB, Cassidy J.

Eur J Cancer. 1994;30A(7):950-5.

PMID:
7946590
21.

N-RAS gene activation in acute myeloid leukemia: association with expression of interleukin-6.

Lübbert M, Oster W, Knopf HP, McCormick F, Mertelsmann R, Herrmann F.

Leukemia. 1993 Dec;7(12):1948-54.

PMID:
8255093
22.

Effect of recombinant human erythropoietin after allogenic bone marrow transplantation.

Link H, Brune T, Hübner G, Diedrich H, Freund M, Stoll M, Peest D, Ebell W, Bettoni C, Oster W, et al.

Ann Hematol. 1993 Oct;67(4):169-73.

PMID:
8218537
23.

Clonal analysis of n-ras gene activation in acute myeloid leukemia.

Lübbert M, Oster W, McCormick F, Mertelsmann R, Herrmann F.

Recent Results Cancer Res. 1993;131:315-27. No abstract available.

PMID:
8210651
24.

A switch toward demethylation is associated with the expression of myeloperoxidase in acute myeloblastic and promyelocytic leukemias.

Lübbert M, Oster W, Ludwig WD, Ganser A, Mertelsmann R, Herrmann F.

Blood. 1992 Oct 15;80(8):2066-73.

26.

Myelosuppressive effects of cytosine arabinoside (Ara-C) on growth factor-dependent human long-term bone marrow cultures (LTBMC).

Kalla P, Oster W, Seiler FR, Rüde E, Krumwieh D.

Int J Cell Cloning. 1992 Jan;10(1):54-62.

PMID:
1552225
27.

Clinical evaluation of erythropoietin (EPO) in oncology.

Oster W, Schindel F, Heinrichs H.

Behring Inst Mitt. 1991 Dec;(90):62-8. Review. No abstract available.

PMID:
1801692
28.

Cytokines in the pathogenesis and management of non-Hodgkin's lymphomas.

Cicco NA, Lübbert M, Oster W, Lindemann A, Mertelsmann R.

Hematol Oncol Clin North Am. 1991 Oct;5(5):1053-66. Review.

PMID:
1938755
29.

Adjuvant therapy with recombinant interleukin-3 and granulocyte-macrophage colony-stimulating factor.

Schulz G, Krumwieh D, Oster W.

Pharmacol Ther. 1991 Oct;52(1):85-94. Review.

PMID:
1805248
30.
31.

Interleukin-3. Biologic effects and clinical impact.

Oster W, Frisch J, Nicolay U, Schulz G.

Cancer. 1991 May 15;67(10 Suppl):2712-7.

PMID:
2015574
32.

Hemopoietins in clinical oncology.

Kanz L, Lindemann A, Oster W, Herrmann F, Mertelsmann R.

Am J Clin Oncol. 1991;14 Suppl 1:S27-33. Review.

PMID:
2048561
33.

New therapeutic modalities for the clinical use of rhGM-CSF in patients with malignancies.

Schulz G, Frisch J, Greifenberg B, Nicolay U, Oster W.

Am J Clin Oncol. 1991;14 Suppl 1:S19-26. Review.

PMID:
2048560
34.

Treatment of patients with anemia of malignancy with recombinant human erythropoietin.

Herrmann F, Oster W, Mertelsmann R.

Contrib Nephrol. 1991;88:238-45; discussion 246-7. Review. No abstract available.

PMID:
2040185
35.

Interleukin 3: biological and clinical effects.

Oster W, Schulz G.

Int J Cell Cloning. 1991 Jan;9(1):5-23. Review. No abstract available.

PMID:
2010655
36.

Clinical use of recombinant human hematopoietic growth factors (GM-CSF, IL-3, EPO) in patients with myelodysplastic syndrome.

Herrmann F, Mertelsmann R, Lindemann A, Ottmann OG, Seipelt G, Oster W, Hoelzer D, Ganser A.

Biotechnol Ther. 1991;2(3-4):299-311.

PMID:
1845132
37.

Interleukin-1, characterization of the molecule, functional activity, and clinical implications.

Brazel D, Nakanishi S, Oster W.

Biotechnol Ther. 1991;2(3-4):241-67. Review.

PMID:
1845129
38.

Effect of rhGM-CSF on haematopoietic reconstitution after chemotherapy in small-cell lung cancer.

Havemann K, Klausmann M, Wolf M, Fischer JR, Drings P, Oster W.

J Cancer Res Clin Oncol. 1991;117 Suppl 4:S203-7.

PMID:
1665493
39.

Interleukin-4 regulates mRNA accumulation of macrophage-colony stimulating factor by fibroblasts: synergism with interleukin-1 beta.

Henschler R, Mantovani L, Oster W, Lübbert M, Lindemann A, Mertelsmann R, Herrmann F.

Br J Haematol. 1990 Sep;76(1):7-11.

PMID:
2223651
40.

Control of blast cell proliferation and differentiation in acute myelogenous leukemia by soluble polypeptide growth factors.

Herrmann F, Oster W, Mertelsmann R.

Klin Padiatr. 1990 Jul-Aug;202(4):212-7. Review.

PMID:
2203937
41.

Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration.

Oster W, Herrmann F, Gamm H, Zeile G, Lindemann A, Müller G, Brune T, Kraemer HP, Mertelsmann R.

J Clin Oncol. 1990 Jun;8(6):956-62.

PMID:
2189957
42.

Synthesis of granulocyte colony-stimulating factor and its requirement for terminal divisions in chronic myelogenous leukemia.

Klein H, Becher R, Lübbert M, Oster W, Schleiermacher E, Brach MA, Souza L, Lindemann A, Mertelsmann RH, Herrmann F.

J Exp Med. 1990 May 1;171(5):1785-90.

43.

Erythropoietin prevents chemotherapy-induced anemia: case report.

Oster W, Herrmann F, Cicco A, Gamm H, Zeile G, Brune T, Lindemann A, Schulz G, Mertelsmann R.

Blut. 1990 Feb;60(2):88-92.

PMID:
2405925
44.

Hematopoietic growth factors in oncology.

Mertelsmann R, Lindemann A, Oster W, Gamm H, Kolbe K, Herrmann F.

Cancer Detect Prev. 1990;14(6):613-6. Review.

PMID:
2257558
45.

Mechanisms of autocrine and paracrine growth control in acute myelogenous leukemia.

Oster W, Mertelsmann R, Hermann F.

Haematol Blood Transfus. 1990;33:8-16. Review. No abstract available.

PMID:
2182467
46.

The role of erythropoietin in patients with anemia and normal renal function.

Oster W, Mertelsmann R.

Contrib Nephrol. 1990;87:26-35. No abstract available.

PMID:
2093538
47.

MACOP-B chemotherapy for the treatment of high grade and intermediate grade non Hodgkin's lymphoma.

Oster W, Forsthuber T, Hennekeuser HH, Gamm H, Lindemann A, Schmitz G, Fuhr HG, Hinterberger R, Kreiter H, Thoenes W, et al.

Blut. 1990 Jan;60(1):23-7.

PMID:
1688725
48.

Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy.

Lindemann A, Herrmann F, Oster W, Haffner G, Meyenburg W, Souza LM, Mertelsmann R.

Blood. 1989 Dec;74(8):2644-51.

49.

Lymphokine activated killer cells.

Lindemann A, Herrmann F, Oster W, Mertelsmann R.

Blut. 1989 Oct;59(4):375-84. Review.

PMID:
2676022
50.

Supplemental Content

Support Center